Key facts
- This page summarizes Daniel J. Starks's Form 4 filing for ABBOTT LABORATORIES (ABT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jul 2022, 17:20.
Daniel J. Starks - 26 Jul 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)
- Reporting relationship
- Director
- Issuer ticker
- ABT
- Reported as of
- 26 Jul 2022
- Net transaction value
- -$5,456,994
- SEC form
- 4
- Accepted by SEC
- 28 Jul 2022, 17:20:11 UTC
- Prior SEC filing
- 05 May 2022
- Next SEC filing
- 31 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel J. Starks filed Form 4 for ABBOTT LABORATORIES (ABT) on 28 Jul 2022.
Change
- Previous filing in this sequence was filed on 05 May 2022.
- Current net transaction value: -$5,456,994.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABT
transaction
Common shares without par value
Sale
- Transaction value
- $3,018,175
- Shares
- -27,749
- Change %
- -0.4%
- Price
- $108.77
- Shares after
- 6,945,751
- Date
- 26 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
ABT
transaction
Common shares without par value
Sale
- Transaction value
- $2,438,819
- Shares
- -22,251
- Change %
- -0.32%
- Price
- $109.60
- Shares after
- 6,923,500
- Date
- 26 Jul 2022
- Ownership
- Direct
- Footnotes
- F2
ABT
holding
Common shares without par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 258
- Date
- 26 Jul 2022
- Ownership
- Alynne Starks 2012 Irrevocable Trust
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.32 to $109.31, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.33 to $109.85 inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F3
Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
SEC remarks
These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).